Abstract
The purpose of this study was to evaluate the efficacy towards acne and the skin surface toxicity of all-trans-retinoyl β-glucuronide (RBG), a naturally occurring retinoid possessing low cytotoxicity and teratogenicity in animal and cell culture studies. In a double-blind study, 15 acne patients treated with 1.2% RBG cream for 16 weeks showed median reductions of 56%, 25% and 67% in total, inflammatory, and noninflammatory lesions, respectively, whereas the placebo group (14 patients) showed median reductions of 31%, 4% and 62%, respectively. The median reduction in total lesions was highly significant in the RBG group (P = 0.002) but not in the placebo group (P = 0.06). In a second initially double-blind study, ten acne patients treated topically for 26 weeks with 0.16–0.32% RBG cream and five patients with 0.1% all-trans-retinoic acid (Retin-A) showed similar responses, i.e. median reductions in total facial lesions of 70% (P = 0.001) and 75% (P = 0.01), respectively. Whereas all subjects treated topica...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
